Breast Cancer Clinical Trial
Official title:
Multidrug Resistance Molecular Target Analysis of Human Samples Collected in Clinical Trials Performed Outside of the Intramural National Cancer Institute
Background:
Resistance to cancer chemotherapy develops in patients, rendering certain treatments
ineffective. Despite much research, the prevailing cause of drug resistance is not known.
One mechanism for drug resistance involves a protein called P-glycoprotein, or Pgp, which
reduces the effectiveness of cancer treatments by "pumping" anti-cancer drugs out of tumor
cells where they are supposed to work against the disease.
Objectives:
To identify and evaluate more thoroughly the roles of Pgp and other substances in mediating
drug resistance.
Eligibility:
Patients enrolled in clinical trials of cancer therapies at the Children's Hospital of
Pittsburgh; Cancer Centers of Carolinas; Arizona Clinical Research Center; University of
Copenhagen; and Herlev Hospital, Copenhagen who have consented to the use of blood, tissue,
or tumor samples for laboratory studies.
Design:
Blood, tumor, and tissue samples are collected from participants and sent to the NCI for
various laboratory analyses.
...
Background:
Ultimately, patients who succumb to cancer do so because of drug resistance. Mechanisms of
drug resistance have been explored in the laboratory and in clinical samples for some time,
yet the prevailing cause of drug resistance, if indeed there is a single cause, is not known.
One mechanism of drug resistance is multidrug efflux, mediated by P-glycoprotein. Other
mechanisms have been proposed. Our laboratory has expertise in the analysis of drug
transporter expression and activity in clinical samples.
Objectives:
To determine expression of P-glycoprotein and other multidrug transporters thought to mediate
clinical drug resistance.
To evaluate inhibition of P-glycoprotein and other multidrug transporters through assessment
of efflux activity in cells obtained from patients enrolled on clinical trials at other
institutions.
To identify and evaluate mechanisms of drug resistance using molecular assays such as cDNA
array, real-time PCR analysis, and immunohistochemistry.
Eligibility:
Patients enrolled on clinical trials outside the NCI, and giving informed consent to the use
of blood, tissue, or tumor samples for evaluation of mechanisms of drug resistance or
evaluation of inhibition of multi-drug efflux.
Future collaborations for similar studies will be added via the protocol amendment procedure;
molecular studies other than ABC transporter assays will be added via the protocol amendment
procedure.
Design:
Human tumor biopsies or blood samples will be collected from cancer patients enrolled on
approved clinical trials, in accordance with the local protocol. These trials are being
conducted at outside institutions, and the samples will be sent to the NCI for
immunohistochemical analysis, cDNA array, PCR analysis, or for blood assays for detection of
P-glycoprotein inhibition.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |